SlowBull
The Business Brief MONDAY, 31 AUGUST 2026
← All stories
Markets

ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy

1 source ·1 article ·1h ago

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·1h ago

ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.